Sign in to view content

Benefits and Value of Treatment for Diabetic Macular Edema

Paul Hahn, MD, PhD, FASRS

Video
Published 2022

Related

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Reduction in the Frequency of Diabetic Macular Edema (DME) Therapies Post-0.2 ug/Day Fluocinolone Acetonide (FAc) Implant Treatment Results
Sam E. Mansour, MD, MSc,FACS, FRCS(C)
Annual Meeting Talks
2018
Does the Diabetic Status Influence the Rate of Cataract Surgery Following Pars Plana Vitrectomy Surgery?
Ahmed Sallam, MD PhD FRCOphth
On Demand Cases, Courses, and Papers
2019

Category: Diabetic Retinopathy

See more